LYON, France, May 07, 2020 -- Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext.
LYON, France, April 06, 2020 -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext.
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the appointment of Melanie Rolli, M.D., to its Board of Directors and the intention to propose the ratification of her appointment at ERYTECH’s next General Meeting of Shareholders. Dr. Rolli has more than 15 years of experience in the global biopharmaceutical and biotechnology industry, including in both Europe and the United States. Dr. Rolli’s appointment follows the resignation of Allene Diaz, who resigned from the Board effective September 30, 2019.
Fast Track designation for eryaspase underscores the urgent need for potential new treatment options for patients with second line metastatic pancreatic cancer LYON, France.
As of late, it has definitely been a great time to be an investor ERYTECH Pharma.
ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the presentation of a Trial in Progress Poster for the ongoing Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer at the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium in San Francisco. TRYbeCA1 is planned to enroll approximately 500 patients in approximately 100 clinical sites in Europe and the U.S. In this trial, eligible patients are randomized 1-to-1 to receive eryaspase in combination with standard chemotherapy (gemcitabine/nab paclitaxel or an irinotecan based regimen) or chemotherapy alone.
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed its 2019 Universal Registration Document for the year ended December 31, 2019, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission (SEC).
LYON, France, March 12, 2020 -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by.
LYON, France and CAMBRIDGE, Mass., Feb. 26, 2020 -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies.
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a public-private consortium supported by the European Union in the framework of the EU Horizon 2020 program. The EVIDENCE consortium, consisting of leading experts in the field of red blood cell research, will explore how red blood cells are influenced by their extra-cellular environment. The EVIDENCE consortium will investigate the behavior of red blood cells under physiological flow conditions, i.e.
Meeting held in closed session on June 26, 2020 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting LYON,.
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, today provided an update on the pivotal Phase 3 clinical trial for advanced metastatic pancreatic cancer (TRYbeCA-1), which is evaluating the efficacy and safety of ERYTECH’s lead product candidate eryaspase in combination with chemotherapy as second-line therapy. “We are pleased that the TRYbeCA-1 trial has continued to progress well despite the challenges caused by the COVID-19 global pandemic,” said Gil Beyen, CEO of ERYTECH.
LYON, France, Feb. 04, 2020 -- Listing markets:Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in.
LYON, France, March 06, 2020 -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market.
Gil Beyen became the CEO of ERYTECH Pharma S.A. (EPA:ERYP) in 2013. This analysis aims first to contrast CEO...
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update. “Our focus during the past several weeks of the COVID-19 pandemic has been to continue our clinical operations and preserving study integrity while ensuring the health of our employees, the patients and the medical professionals involved in our clinical programs,” said Gil Beyen, CEO of ERYTECH Pharma. With more than 75% of patients enrolled in the TRYbeCA-1 Phase 3 trial and based on the event rate observed thus far, we expect to report the results of the interim superiority analysis around year-end of 2020 and the final result in the second half of 2021.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the fourth quarter and year ended December 31, 2019. “2019 has been a year of tremendous execution towards realizing our vision of helping cancer patients to live longer and better,” said Gil Beyen, CEO of ERYTECH.
ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that it has entered into a strategic partnership with the German Red Cross Blood Donor Service Baden-Württemberg-Hessen (GRCBDS) to complement the existing alliance with the French Blood bank (EFS) for the supply of donor red blood cells to manufacture its product candidates, including eryaspase, in Europe. The GRCBDS is one of the world’s largest blood and transfusion services, ensuring safe and adequate supply of blood products for approximately 30 million Germans (more than one-third of the German population).
LYON, France, April 30, 2020 -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by.